Invesco DB Commodity Index Tracking Fund vs Danaher Corporation — how do they compare? Invesco DB Commodity Index Tracking Fund trades at $33.01 (market cap $1.92B), while Danaher Corporation trades at $217.88 (market cap $152.87B). The key difference: Danaher Corporation is far larger — about 79.6× Invesco DB Commodity Index Tracking Fund's market cap, and Danaher Corporation pays a 0.74% dividend while Invesco DB Commodity Index Tracking Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Commodity Index Tracking Fund for 61 Days and Danaher Corporation for 69 Days on average.
| DBC | DHR | |
|---|---|---|
Market Cap | $1.92B | $152.87B |
Volume | 1,375,556 | 5,228,698 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $33.68 | $242.05 |
52-Week Low | $22.07 | $161.91 |
Typical Hold Time | 61 Days | 69 Days |
Enterprise Value | — | $175.08B |
Dividend Yield | — | 0.74% |
Signals from Pluang's Aura AI — not financial advice
DBC trades at $32.51, down 0.55% today, with a bullish technical signal from moving averages. The company reported $82.59M revenue and $22.38M net income for 2024, showing improved profitability with a 27.1% margin. Cash flow from operations was strong at $431.54M, though total assets declined from $2.7B in 2021 to $1.29B currently. Technical indicators show support at $32 and resistance at $33.
DBC demonstrates solid operational cash generation despite asset base contraction. The zero-debt balance sheet provides financial stability, but declining revenue from 2023's $108M raises growth concerns. Current valuation metrics remain undisclosed, requiring deeper analysis. The stock's technical strength suggests near-term upside potential if fundamental performance stabilizes.
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →